Introduction {#S1}
============

Allogeneic hematopoietic stem cell transplantation (HSCT) is a treatment of high-risk leukemia and a number of benign hematological disorders. In the treatment of leukemia, the outcome of HSCT is based on an immune-mediated cytotoxic attack on the malignant cells and persisting immune surveillance, also known as the graft-versus-leukemia effect. However, the success of HSCT is limited by long-lasting T cell dysfunction with risk of severe infections and development of graft-versus-host disease (GVHD), both contributing significantly to non-relapse mortality ([@B1]--[@B3]). More detailed insight into the mechanisms of T cell reconstitution and prognostic markers is essential to limit morbidity and mortality after HSCT.

Interleukin-7 (IL-7) is a hematopoietic cytokine essential for *de novo* T cell development in the thymus and homeostatic peripheral expansion of T cells ([@B4]--[@B6]). IL-7 signals through the IL-7 receptor (IL-7R), a heterodimer consisting of the common γ-chain (CD132) and the high-affinity IL-7R α-chain (IL-7Rα, CD127) ([@B7]). The IL-7Rα-chain is also used by Thymic Stromal Lymphopoetin, a cytokine promoting TH2 differentiation and Treg induction, and involved in allergic inflammation and autoimmunity ([@B8]--[@B12]).

Interleukin-7 receptor α-chain is expressed on lymphocyte progenitors and on naïve and memory T cells, and its expression is strictly regulated during the different developmental stages of T cells with the highest expression on naïve T cells, a lower expression on memory T cells, and downregulation of IL-7Rα upon development into effector T cells ([@B6], [@B13]). The critical role of the IL-7 pathway for human T cell homeostasis is illustrated by the fact that absence of a functioning IL-7Rα leads to severe combined immunodeficiency with a T-B + NK + phenotype ([@B14]), while somatic gain-of-function mutations in IL-7Rα may cause T- as well as B-cell acute lymphoblastic leukemia ([@B15], [@B16]).

Single nucleotide polymorphisms (SNPs) in the exons of the IL-7Rα, which give rise to non-conservative amino-acid substitutions, have been associated with several chronic inflammatory diseases. The *rs6897932* SNP in the transmembrane region of the IL-7Rα increases the risk of developing multiple sclerosis, ulcerative colitis, and sarcoidosis ([@B17]--[@B20]). In allogeneic HSCT, donor genotypes of SNPs influencing the structure of the extracellular part of IL-7Rα have been associated with non-relapse mortality after allogeneic HSCT, in contrast to recipient genotypes that were not associated with outcomes ([@B21]--[@B23]).

In this study, we show that the donor genotype in IL-7Rα *rs6897932* influences the rate of immune reconstitution after allogeneic HSCT with impact on infections as well as acute GVHD (aGVHD) and chronic GVHD (cGVHD).

Materials and Methods {#S2}
=====================

Patient Population {#S2-1}
------------------

We retrospectively studied patients undergoing allogeneic transplantation at the national HSCT center at Copenhagen University Hospital Rigshospitalet, Denmark, from 2004 to 2014. Inclusion criteria were first allogeneic HSCT, myeloablative conditioning ([@B24]), a matched sibling donor or an unrelated donor, and the use of bone marrow or peripheral blood as stem cell source.

Five-hundred twelve patients fulfilled the inclusion criteria. Deposited donor blood samples were available for 471 of these, and a donor SNP could be assigned for 460 patients (89.8%), which were all included in the study. The included patients did not differ significantly from non-participants in terms of age, diagnosis, donor, conditioning regimen, graft type, cell dose/kilogram, pre-transplant Karnofsky score, sex-mismatch, or cytomegalovirus (CMV) antibody status.

The study protocol was approved by the ethics committee of the Capital Region of Denmark (\#H-15006001), and written informed consent was obtained from all patients and/or their legal guardians.

Patient Characteristics {#S2-2}
-----------------------

The study included 153 children and 307 adults with a median age of 26.3 years (range 0.3--63.0 years). Diagnosis was acute myeloid leukemia (*n* = 136), acute lymphoblastic leukemia (*n* = 118), myelodysplastic syndrome (*n* = 51), chronic myeloid leukemia (*n* = 39), other malignancies (*n* = 28), or benign diseases (*n* = 88, including 46 severe aplastic anemia and 24 primary immunodeficiencies). Donors were either fully human leukocyte antigen-A, -B, -C, -DR, and -DQ allele-matched sibling donors (*n* = 147), matched unrelated donors (10/10 match, *n* = 244), or mismatched unrelated donors (9/10 or 8/10 match, *n* = 69). Bone marrow (*n* = 329) or G-CFS mobilized peripheral blood stem cells (*n* = 131) were used as stem cell source, and allografts were T cell replete. Conditioning regimens consisted of total body irradiation (TBI) plus cyclophosphamide or etoposide (*n* = 293), cyclophosphamide plus busulphane (*n* = 107), or other types of chemotherapy-based conditioning (*n* = 60). Conditioning included anti-thymocyte globulin (ATG) in 179 patients transplanted with an unrelated donor. GVHD prophylaxis consisted of Cyclosporine A plus methotrexate for 90% of patients. All patients were monitored weekly by PCR for viral infections (reactivation or primary infection) with CMV and Epstein--Barr virus (EBV) until day +90 post-HSCT and subsequently every second week. In case of increasing viral load, pre-emptive treatment with anti-viral medication \[(Val)ganciclovir for CMV infection and Rituximab for EBV infection\] was commenced along with tapering of immunosuppression.

Detection of IL-7Rα SNPs {#S2-3}
------------------------

Blood from donors were collected before HSCT and stored at −20°C. Genomic DNA extraction was performed using Maxwell™ 16 Blood DNA Purification Kit (Promega Biotech AB, Nacka, Sweden) as described by the manufacturer.

DNA was genotyped for *rs6897932* using a previously described multiplex bead-based assay ([@B25]). In brief, allele-specific primers were labeled in a primer extension using polymerase chain reaction-amplified SNP-sites as their target regions. The labeled primers were then hybridized to MicroPlex-xTAG beadsets for detection and counting on the Luminex platform (Luminex Corporation, Austin, TX, USA). We also included primers for the sex-specific amelogenin-gene ("AMELX" and "AMELY," respectively) to be able to define the sex of the donor as a quality control ([@B26]).

All donor samples were blinded to the technicians performing the analyzes. The IL-7Rα SNP calling rates were 99.4%, and 10% of samples were genotyped twice without discordance. Eight samples were excluded due to mismatch between sex according to sex determined by the amelogenin-gene and known donor sex.

Immunological Parameters {#S2-4}
------------------------

Absolute lymphocyte counts were measured as part of the clinical routine by particle counting using Sysmex XN flow cytometry. Total immunoglobulins (IgM, IgG, and IgA) were measured with turbidimetry using Cobas 8000, module c502.

T and B cells were counted 12 months after HSCT, and in addition measured after 1, 2, 3, and 6 months in patients undergoing HSCT from 2008 to 2014 (*n* = 283, 62%). Peripheral blood samples were analyzed directly in a single-platform no-lyse-no-wash flow cytometry procedure. EDTA-anti-coagulated blood were incubated in Trucount tubes (Becton, Dickinson & Company, Albertslund, Denmark) for quantification of lymphocyte subsets, and a panel of monoclonal antibodies (CD3-PerCP, CD3-FITC, CD4-FITC, CD8-PE, CD45-PerCP, and CD19-PE, all from BD) on a FC500 flow cytometer (Beckman Coulter, Copenhagen, Denmark). Lymphocytes were gated based on forward scatter and side scatter characteristics. Lymphocyte subsets were identified as CD3+ T cells, CD4+ T cells, CD8+ T cells, and CD45+ CD19+ B cells. The laboratory participates in the quality assurance program by the National External Quality Assessment Site (NEQAS).

Statistical Analysis {#S2-5}
--------------------

Kaplan--Meier estimates with log-rank tests were applied as an initial non-parametric analysis of the risk of complications and mortality. Next, a cause-specific Cox regression model was used to estimate the risk of aGVHD, cGVHD, viral reactivation, and time to lymphocyte recovery. Overall survival was analyzed further using Cox regression, while treatment-related mortality (TRM) and relapse were estimated using Fine--Gray competing risk regression model. For all analyzes, transplant-related characteristics that are main risk factors for the specific transplant-related complications were included in the multivariable model for this outcome as indicated under results.

Linear regression analyzes were used to analyze associations with cell counts and immunoglobulin levels after 1 year. Longitudinal analysis of T cell counts were performed with a linear mixed model with random slope over time since transplantation and random intercept by patient for measurements from all patients without truncation due to death, relapse, retransplantation, or donor lymphocyte infusion within the first 360 days. All cell counts were log10-transformed; and measurements equal to 0 (3.2%) were changed to 0.005 × 10^9^/L corresponding to one half of the minimum value of the measurements. For the multivariable analysis, all potential co-variables were included in the model and analyzed with backwards elimination. The final model included recipient age, stem cell source, ATG, and the IL-7Rα genotype. In an additional backwards elimination model, aGVHD and cGVHD were included as time-dependent variables and remained significant together with recipient age, stem cell source, ATG, and the IL-7Rα genotypes.

To confirm these results regarding T cell counts in a model including patients, who experienced death, relapse, retransplantation, or donor lymphocyte infusion within the first 360 days, we performed a pattern mixture model including all patients and with truncation at time of the event. This model analyzed the cell counts in each stratum (defined by time of event/truncation) in turn using a standard linear mixed model. The mixed model contained a random intercept by patient and, whenever feasible due to enough data in a stratum, a random slope by time since transplantation. The IL-7Rα genotypes were compared as major allele homozygotes (CC) versus heterozygotes and minor allele homozygotes combined (CT/TT) due to limited data within each stratum in the minor allele homozygous patients. Missing and truncated were similarly distributed in the genotype groups.

A two-sided *P*-value \<0.05 was considered statistically significant. All statistical analyzes were performed using R statistical software version 3.2.3 (R Foundation for Statistical Computing, Vienna, Austria).

Results {#S3}
=======

IL-7Rα Genotypes and Transplantation Characteristics {#S3-1}
----------------------------------------------------

The frequencies of the *rs6897932* genotype in donors \[CC = 252 (55.8%), CT = 178 (38.7%), and TT = 30 (6.5%)\] corresponded to previously reported gene frequencies, and the distribution of genotypes met the criteria for Hardy--Weinberg equilibrium.

Table [1](#T1){ref-type="table"} shows the transplantation characteristics divided among the *rs6897932* genotypes. No significant differences were found between patients in the three different groups.

###### 

Transplantation characteristics by donor Interleukin-7 receptor α-chain genotype *rs6897932*.

  Characteristics                                                        CC (*n* = 252)     CT (*n* = 178)     TT (*n* = 30)       *P*-value
  ---------------------------------------------------------------------- ------------------ ------------------ ------------------- -----------
  **Age at transplantation (years), median (range)**                                                                               
  Recipients                                                             25.4 (0.4--63.0)   27.8 (0.3--60.0)   27.6 (0.9--50.6)    0.61
  Donors                                                                 34.0 (2.8--71.6)   33.0 (1.1--59.5)   35.6 (16.1--60.8)   0.27
  **Disease at transplantation, no. of patients (%)**                                                                              
  Acute myeoloid leukemia                                                78 (31%)           50 (28%)           8 (27%)             0.89
  Acute lymphoblastic leukemia                                           62 (25%)           48 (27%)           8 (27%)             
  Other malignancies                                                     65 (26%)           43 (24%)           10 (33%)            
  Benign disorders                                                       47 (19%)           37 (21%)           4 (13%)             
  **Donor type, no. (%)**                                                                                                          
  HLA-identical. siblings                                                78 (31%)           57 (32%)           12 (40%)            0.81
  HLA-matched unrelated donors                                           133 (53%)          97 (54%)           14 (47%)            
  HLA-mismatched unrelated donors                                        41 (16%)           24 (13%)           4 (13%)             
  **Stem cell source, no. (%)**                                                                                                    
  Bone marrow stem cells                                                 181 (72%)          130 (73%)          18 (60%)            0.34
  Peripheral blood stem cells, G-CSF mobilized                           71 (28%)           48 (27%)           12 (40%)            
  **Total nucleated cell dose infused ×10^6^/kg recipient wt, median**   4                  3.6                5                   0.29
  **Conditioning regimen, no. of patients (%)**                                                                                    
  TBI + CY or Etoposide                                                  156 (62%)          116 (65%)          21 (70%)            0.61
  Chemotherapy alone                                                     96 (38%)           62 (35%)           9 (30%)             
  **Anti-thymocyte globulin as part of conditioning regimen, no. (%)**                                                             
  Yes                                                                    105 (42%)          65 (37%)           9 (30%)             0.34
  No                                                                     147 (58%)          113 (63%)          21 (70%)            
  **Sex-mismatch (female donor to male recipient), no. (%)**                                                                       
  Yes                                                                    37 (15%)           27 (15%)           7 (23%)             0.46
  No                                                                     215 (85%)          151 (85%)          23 (77%)            
  **CMV IgG mismatch, no. (%)**                                                                                                    
  Yes                                                                    91 (36%)           61 (34%)           10 (33%)            0.86
  No                                                                     161 (64%)          117 (66%)          20 (67%)            

Donor *rs6897932* Genotype and aGVHD {#S3-2}
------------------------------------

251 patients (54.6%) developed aGVHD with onset at median day +24 (+6 to +106) post-HSCT; grades III--IV aGVHD were seen in 42 patients (9.1%). The risk of grades III--IV aGVHD was significantly increased in donors with one or two copies of the T allele in *rs6897932* (12.5% for CT/TT versus 6.3% for CC, *P* = 0.023) (Figure [1](#F1){ref-type="fig"}; Table S1 in Supplementary Material). This was confirmed in a multivariable Cox regression after adjustment for recipient age, donor type (matched sibling donor/matched unrelated donor/mismatched unrelated donor), stem cell source, cell dose/kilogram, TBI-based conditioning, ATG, and sex-mismatch (HR = 2.0, 95% CI = 1.1--3.8, *P* = 0.036 for TT/CT compared with the CC genotype).

![Incidence of acute graft-versus-host disease (aGVHD) following hematopoietic stem cell transplantation (HSCT) according to donor's genotype in the Interleukin-7 receptor α-chain single nucleotide polymorphism *rs6897932*. **(A)** Relative frequency of aGVHD and **(B)** Kaplan--Meier estimates of aGVHD grades III--IV. **(C--E)** Organ staging of aGVHD. The *P*-value indicates the difference between donor genotype CT/TT and CC (genotype distribution: CC: *n* = 252, CT: *n* = 178, TT: *n* = 30).](fimmu-09-00109-g001){#F1}

Donor *rs6897932* Genotype and cGVHD {#S3-3}
------------------------------------

Extensive cGVHD occurred in 118 patients (25.7%) at median day +201 (+42 to +2,088), and this was significantly associated with donor *rs6897932* genotype with a step-wise increased risk of cGVHD for each T allele (CC: 21.8%, CT: 27.0%, and TT: 50.0%, *P* = 0.0031) (Figure [2](#F2){ref-type="fig"}; Table S1 in Supplementary Material). The risk of extensive cGVHD was significantly increased for the TT versus CC genotype in a multivariable Cox regression adjusting for recipient age, donor type (matched sibling donor/matched unrelated donor/mismatched unrelated donor), stem cell source, cell dose/kilogram, TBI-based conditioning, ATG, and sex-mismatch (HR = 2.0, 95% CI = 1.1--3.6, *P* = 0.025).

![Incidence of chronic graft-versus-host disease (cGVHD) following hematopoietic stem cell transplantation (HSCT) according to donor's genotype in the Interleukin-7 receptor α-chain single nucleotide polymorphism *rs6897932*. **(A)** Relative frequency of cGVHD and **(B)** Kaplan--Meier estimates of extensive cGVHD. The *P*-value indicates the difference between donor genotype TT and CC (genotype distribution: CC: *n* = 252, CT: *n* = 178, TT: *n* = 30).](fimmu-09-00109-g002){#F2}

To address if the effect of the donor genotype on chronic GVHD was mediated by the increased risk of aGVHD, we included aGVHD in a Cox regression model also adjusting for recipient age, donor type, stem cell source, cell dose/kilogram, TBI-based conditioning, ATG, and sex-mismatch. In this modified model, the donor *rs6897932* genotype remained an independent risk factor of extensive cGVHD (HR = 1.9, 95% CI = 1.0--3.5, *P* = 0.035).

Donor *rs6897932* Genotype and Viral Infections {#S3-4}
-----------------------------------------------

123 patients (26.7%) developed therapy-requiring CMV infection at median day +49 post-HSCT, and 34 patients (7.4%) developed therapy-requiring EBV infection at median day +57.

Donor *rs6897932* TT genotype was associated with a higher occurrence of CMV infection compared with CC (CC: 23.8%, CT: 31.4%, and TT: 43.3%, *P* = 0.053) (Figure [3](#F3){ref-type="fig"}; Table S1 in Supplementary Material). The risk of CMV infection post-HSCT was significantly increased with HR = 2.3 (95% CI = 1.2--4.3, *P* = 0.0083) for TT versus CC genotype in a multivariable Cox regression model adjusting for recipient age, donor type (matched sibling donor/matched unrelated donor/mismatched unrelated donor), stem cell source, cell dose, TBI-based conditioning, ATG and CMV mismatch between donor and recipient (D−R+ or D+R−). No association with EBV infection was observed.

![Incidence of cytomegalovirus (CMV) infection following hematopoietic stem cell transplantation (HSCT) according to donor's genotype in the Interleukin-7 receptor α-chain single nucleotide polymorphism *rs6897932*. Kaplan--Meier estimates of treatment-requiring CMV infection are shown. The *P*-value indicates the difference between donor genotype TT and CC (genotype distribution: CC: *n* = 252, CT: *n* = 178, TT: *n* = 30).](fimmu-09-00109-g003){#F3}

Donor *rs6897932* Genotype and Early Lymphocyte Reconstitution {#S3-5}
--------------------------------------------------------------

Lymphocyte recovery with \>10^9^ lymphocytes/L occurred in 427 patients (92.8%) within the first year post-HSCT. There was no association between donor *rs6897932* genotype and time to lymphocyte recovery.

We further investigated the impact *rs6897932* on recovery of T and B lymphocyte subsets within 1 year post-HSCT. Patients were excluded from the analysis in case of death, relapse, retransplantation, or donor lymphocyte infusion from the date of the event.

First, we studied the impact on immune reconstitution in a linear mixed model only including patients, who did not experience an event within the first 360 days (*n* = 212). In an univariable model, the donor *rs6897932* genotype TT was associated with significantly increased CD3+, CD4+, and CD8+ T cells at day +60 compared with the CC genotype (Figure [4](#F4){ref-type="fig"}). This was confirmed in the multivariable model, where the donor TT genotype was associated with an increased number of T cell subsets (CD3+: 109% increase, *P* = 0.0096; CD4+: 64% increase, *P* = 0.038; CD8+: 133% increase, *P* = 0.011) at day +60 compared with the CC genotype, after adjustment for age, stem cell source, and ATG (Table [2](#T2){ref-type="table"}). These results were similar, when also adjusting for the immunosuppressive effect of aGVHD and cGVHD by including them as time-dependent co-variables in this model (*P* = 0.0079, *P* = 0.030, and *P* = 0.0096, respectively).

![Early immune reconstitution following hematopoietic stem cell transplantation (HSCT) according to donor's genotype in the Interleukin-7 receptor α-chain single nucleotide polymorphism *rs6897932*. **(A--C)** Median CD3+, CD4+, and CD8+ T cell counts from time of transplantation to 3 months post-HSCT. The *P*-values indicate the difference between donor genotype TT and CC at the specific time point in a longitudinal linear mixed model (\**P* \< 0.05, \*\**P* \< 0.01) (genotype distribution: CC: *n* = 108, CT: *n* = 86, TT: *n* = 18).](fimmu-09-00109-g004){#F4}

###### 

Longitudinal T cell reconstitution by donor Interleukin-7 receptor α-chain genotype.

                 Univariable model \[estimate (95% CI)\]   Multivariable model \[estimate (95% CI)\]                                                                                                       
  -------------- ----------------------------------------- ------------------------------------------- ------ ----------------------- ----------- ----- ------------------- ------ ----------------------- ------------
  **Day +30**                                                                                                                                                                                              
  CD3+           1.0                                       0.90 (0.61--1.32)                           0.59   1.37 (0.71--2.64)       0.34        1.0   0.94 (0.67--1.33)   0.75   1.04 (0.57--1.90)       0.89
  CD4+           1.0                                       0.97 (0.69--1.37)                           0.85   1.68 (0.93--3.05)       0.088       1.0   1.03 (0.77--1.38)   0.86   1.27 (0.76--2.10)       0.36
  CD8+           1.0                                       0.91 (0.61--1.38)                           0.67   1.19 (0.58--2.44)       0.63        1.0   0.95 (0.64--1.41)   0.79   0.96 (0.48--1.92)       0.92
  **Day +60**                                                                                                                                                                                              
  CD3+           1.0                                       1.16 (0.81--1.67)                           0.42   **2.37 (1.29--4.35)**   **0.006**   1.0   1.20 (0.86--1.67)   0.30   **2.09 (1.20--3.66)**   **0.0097**
  CD4+           1.0                                       1.08 (0.78--1.50)                           0.63   **1.94 (1.13--3.37)**   **0.017**   1.0   1.13 (0.86--1.50)   0.38   **1.64 (1.03--2.61)**   **0.038**
  CD8+           1.0                                       1.24 (0.83--1.86)                           0.29   **2.53 (1.29--4.96)**   **0.007**   1.0   1.26 (0.85--1.86)   0.24   **2.33 (1.21--4.47)**   **0.011**
  **Day +90**                                                                                                                                                                                              
  CD3+           1.0                                       1.02 (0.73--1.44)                           0.89   1.36 (0.70--2.64)       0.36        1.0   1.02 (0.74--1.39)   0.91   1.22 (0.66--2.27)       0.53
  CD4+           1.0                                       0.99 (0.74--1.34)                           0.97   1.53 (0.85--2.73)       0.16        1.0   1.01 (0.78--1.30)   0.96   1.28 (0.77--2.15)       0.34
  CD8+           1.0                                       1.03 (0.71--1.51)                           0.86   1.35 (0.64--2.83)       0.43        1.0   1.03 (0.71--1.48)   0.89   1.26 (0.61--2.59)       0.53
  **Day +180**                                                                                                                                                                                             
  CD3+           1.0                                       1.00 (0.74--1.36)                           0.99   0.94 (0.55--1.59)       0.81        1.0   0.99 (0.74--1.33)   0.95   0.86 (0.52--1.43)       0.56
  CD4+           1.0                                       0.98 (0.75--1.28)                           0.86   1.13 (0.71--1.80)       0.61        1.0   0.97 (0.76--1.23)   0.80   1.01 (0.66--1.53)       0.97
  CD8+           1.0                                       0.94 (0.66--1.35)                           0.74   0.80 (0.43--1.49)       0.48        1.0   0.93 (0.66--1.33)   0.71   0.76 (0.41--1.40)       0.38
  **Day +360**                                                                                                                                                                                             
  CD3+           1.0                                       0.97 (0.72--1.31)                           0.83   0.93 (0.53--1.63)       0.79        1.0   0.94 (0.71--1.24)   0.67   0.91 (0.54--1.55)       0.74
  CD4+           1.0                                       0.92 (0.67--1.25)                           0.59   1.04 (0.58--1.86)       0.90        1.0   0.89 (0.68--1.16)   0.38   0.98 (0.59--1.63)       0.95
  CD8+           1.0                                       0.98 (0.69--1.39)                           0.90   0.87 (0.45--1.66)       0.67        1.0   0.95 (0.68--1.34)   0.77   0.86 (0.45--1.63)       0.64

*Significant associations are written in bold*.

Next, we investigated the significance of IL-7Rα donor genotypes in a pattern mixture model with truncation due to death, relapse, retransplantation, or donor lymphocyte infusion to confirm the first results in a cohort including patients who experienced an event (*n* = 268). At each time of follow-up, the expected change in median cell count were estimated and compared between the genotype groups. The two groups CT and TT were merged to be able to estimate all parameters, due to the limited number of donors with the TT genotype. In this model, no significant difference between cell counts for the *rs6897932* genotype was found at any time point, most likely due to the limited data in each strata. Notably, missing and truncated patients were similarly distributed in the two genotype-defined groups.

Donor *rs6897932* Genotype and Late Immunity {#S3-6}
--------------------------------------------

We next assessed the major immune parameters 1 year after HSCT. Measurements of T and B cells were available in 233 (72.6%) patients having no events before this time point. There was no difference in cell counts of any lymphocyte subsets according to the *rs6897932* genotype in a linear regression model both before and after adjustment for age, stem cell source, and ATG (Figures [5](#F5){ref-type="fig"}A--D; Table [2](#T2){ref-type="table"}).

![Immunity at 1 year post-hematopoietic stem cell transplantation according to donor's genotype in the Interleukin-7 receptor α-chain single nucleotide polymorphism *rs6897932*. **(A--D)** Total counts of CD3+, CD8+, and CD4+ T cells and CD19+ B cells. **(E--G)** Plasma levels of immunoglobulins (median plus quartiles). The *P*-values indicate the difference between donor genotype TT and CC (\**P* \< 0.05) (genotype distribution: CC: *n* = 128, CT: *n* = 90, TT: *n* = 15).](fimmu-09-00109-g005){#F5}

We looked into the level of immunoglobulins to evaluate the functional interaction between T and B cells. The donor *rs6897932* TT genotype was associated with significantly lower levels of IgG and IgM compared to the CC genotype 1 year post-HSCT (Figures [5](#F5){ref-type="fig"}E--G), although no difference was observed before transplantation. This finding remained significant for IgG in a multivariable model adjusting for age, stem cell source, and ATG (*P* = 0.027). However, this decrease in immunoglobulin levels was also strongly associated with occurrence of aGVHD and cGVHD, suggesting that the immunosuppressive effect of *rs6897932* on late immunity might be mediated through an increased allo-response.

Donor *rs6897932* Genotype and Mortality {#S3-7}
----------------------------------------

We next investigated whether the *rs6897932* donor genotype also influenced post-transplant mortality. 156 patients (33.9%) died within the follow-up time of 6.9 years (range: 1.9--12.8). Of patients transplanted for a malignant disease, 78 patients (21.0%) died of TRM and 81 patients (21.8%) relapsed.

Donor carriage of the *rs6897932* CT genotype was associated with inferior overall survival in an univariable Cox regression model (HR = 1.50, *P* = 0.013) (Figure [6](#F6){ref-type="fig"}A; Table S1 in Supplementary Material) as well as in a multivariable model adjusting for recipient age, diagnosis, donor type, stem cell source, TBI-based conditioning, and ATG (HR = 1.7 for CT versus CC genotype, 95% CI = 1.2--2.3, *P* = 0.0027).

![Mortality following hematopoietic stem cell transplantation (HSCT) according to donor's genotype in the Interleukin-7 receptor α-chain single nucleotide polymorphism *rs6897932*. **(A)** Overall survival, **(B)** treatment-related mortality (TRM), and **(C)** relapse frequency. Overall survival is estimated by Kaplan--Meier, while TRM and relapse are estimated by a Fine--Gray competing risk model. The *P*-values indicate the difference between donor genotype CT and CC (genotype distribution: CC: *n* = 252, CT: *n* = 178, TT: *n* = 30).](fimmu-09-00109-g006){#F6}

In a competing risk model, donor *rs6897932* CT genotype was associated with increased TRM in a univariable model (cumulative incidence estimates: CC = 14.3%, CT = 35.0, TT = 19.6%, *P* = 0.00022 for CT versus CC genotype), but not with the risk of relapse (*P* = 0.35) (Figures [6](#F6){ref-type="fig"}B,C; Table S1 in Supplementary Material). The significant association with TRM was confirmed in a multivariable competing risk model adjusted for recipient age, donor type, stem cell source, TBI-based conditioning, and ATG (HR = 2.3, 95% CI = 1.3--4.0, *P* = 0.0047 for CT versus CC). We were not able to demonstrate a significant effect of TT homozygosity on TRM most likely reflecting the low prevalence of this genotype.

Discussion {#S4}
==========

Despite the marked improvements during the recent years, allogeneic HSCT is still challenged by severe treatment-related complications ([@B27]). Both aGVHD and cGVHD cause significant morbidity and mortality after HSCT, and the long-term immunosuppressive treatment of these complications may have limited efficacy although still hampering the immune responses toward infections and the remaining leukemic cells ([@B28]). Thus, identification of risk factors for development of alloreactivity and immune dysfunction may be an important step toward a more effective risk stratification to prevent these complications.

Our data show that donor *rs6897932* TT genotype in the IL-7Rα is associated with increased risk of both aGVHD and cGVHD, CMV infection, and faster reconstitution of T cells. These results indicate that genotyping of *rs6897932* could help to individualize conditioning regimens and GVHD prophylaxis, or potentially be included as a supplementary criteria for donor selection along with HLA-typing. As alloreactivity and the graft-versus-leukemia effect are often closely associated ([@B27]), it is of particular interest that the impact of the *rs6897932* genotype is restricted to treatment-related complications with no significant impact on relapse.

The *rs6897932* SNP has been studied previously in low-powered or heterogeneous multicenter studies with conflicting results concerning aGVHD and mortality ([@B21]--[@B23], [@B29], [@B30]). A major strength of the present study is the large number of HSCT patients studied within a single institution with an ethnically homogeneous population and a uniform registration of complications. However, in comparison with genetic studies linking candidate SNPs to development of disease in general, our cohort is relatively small and results should be taken with caution, especially considering the low frequency of the risk genotype.

Interleukin-7 is a cytokine with effects on both peripheral expansion of T cells and thymic T cell production that is known to decline with age ([@B31], [@B32]). Accordingly, we found it important to address age-related differences in the impact of the IL-7Rα SNP. In an age-stratified analysis, we found similar associations with clinical outcomes and T cell reconstitution in adult and pediatric patients suggesting that the effects of the genotype were independent on age-related changes in thymic function. In line with this, the IL-7Rα SNP appeared to affect T cell numbers at an early stage before day 100 where thymic output in the form of T cell receptor excision circles cannot be detected ([@B33]--[@B35]), suggesting that *rs6897932* is mainly affecting the peripheral expansion of T cells of importance for both children and adults in the early post-transplant period.

The biological background for the impact of *rs6897932* on immune dysregulation in allo- and autoimmunity has been addressed previously. Studies in conditions with elevated IL-7 levels, due to lymphopenia or pharmacologic administration of IL-7, indicate that IL-7 in high concentrations may enhance the proliferative responses even to weak *self*-antigens ([@B36]--[@B38]). Therefore, it is likely that IL-7 may also drive peripheral expansion of naïve alloreactive T cell clones early after HSCT, where IL-7 levels are highly increased ([@B39]--[@B41]). Furthermore, recent studies suggest that IL-7 specifically enhances the proliferation of pro-inflammatory T cell subsets ([@B42], [@B43]) and reduce the functional capacity of regulatory T cells to suppress proliferation and cytokine production ([@B44]). In line with this, elevated IL-7 levels are associated with development of aGVHD after myeloablative HSCT and is increased in autoimmune diseases ([@B39]--[@B41], [@B45]).

The mechanism by which *rs6897932* impacts outcome of HSCT is most likely related to an altered degree of binding of IL-7 to soluble IL-7R (sIL-7R). The T allele in *rs6897932* causes an amino-acid substitution in the transmembrane region of the IL-7Rα gene which reduces alternative splicing of this domain. This process results in increased expression of membrane-bound IL-7R and decreased generation of sIL-7R ([@B46], [@B47]). Since sIL-7R acts as an inhibitor of IL-7 signaling *in vitro* ([@B48]), *rs6897932* may affect IL-7 activity not only by diminishing sIL-7R levels, but also through increased expression of membrane-bound IL-7Rα.

Several lines of evidence suggest that the T allele of *rs6897932* increases IL-7 activity. First, the T allele is associated with faster CD3+, CD4+, and CD8+ T cell reconstitution early post-HSCT as shown here. These results correspond to studies in T cell depletion caused by human immunodeficiency virus, where the *rs6897932* T allele and low-sIL-7R levels were associated with a more rapid CD4+ T cell recovery after anti-retroviral treatment ([@B49]). Furthermore, *rs6897932* T allele has been associated with increased intracellular STAT-5 signaling in CD4+ T cells after *in vitro* stimulation with IL-7, resulting in increased cellular proliferation ([@B50]). In allogeneic HSCT, the increased homeostatic proliferation and survival of T cells from donors with the *rs6897932* TT genotype are likely a contributing reason for the increased risk of GVHD observed here.

Secondly, the T allele is associated with reduced plasma levels of sIL-7R that are related to aGVHD ([@B30], [@B51]). This is, however, in contrast to the findings in chronic inflammatory diseases, where the *rs6897932* C allele and elevated sIL-7R levels have been identified as risk factors for developing multiple sclerosis, ulcerative colitis, sarcoidosis, inhalation allergy, and type 1 diabetes ([@B17]--[@B20], [@B52]--[@B57]). The explanation for this apparent inconsistency may relate to the limited levels of IL-7 seen in these autoimmune conditions compared with the HSCT setting, where IL-7 levels are many-fold above normal levels. A recent study suggested that sIL-7R is inhibitory at short-term, while overall potentiating the bioavailability of IL-7 by protecting the cytokine from consumption ([@B58]). In HSCT, however, the scenario is much different due to the supra-physiological levels of IL-7 in combination with severely depressed sIL-7R levels in the early post-transplant period ([@B30], [@B51]). Under these extreme conditions, even a short-term inhibition mediated by high sIL-7R may be enough to protect against alloreactivity, and thereby explain the lower incidence of GVHD in transplantations with a donor CC genotype.

Recent studies also suggest an importance of IL-7Rα mediated signals for normal human B cell production ([@B59]), although patients with SCID caused by a defect IL-7Rα signaling have normal B cell numbers ([@B14]). Our results do not suggest an association between IL-7Rα SNPs and quantitative B cell reconstitution following HSCT, but show significantly decreased IgG levels after 1 year in patients transplanted with the *rs6897932* TT genotype. This could not be related to a difference in T or B cell counts that were similar among the genotypes at this time point, although a functional impact on T cell subsets required for isotype switch and antibody production cannot be excluded. Importantly, however, our multivariable analysis suggested that the effect of this genotype on immunoglobulin levels may be mediated through cGVHD, suppressing bone marrow function (including the plasma cells) and thymopoiesis directly as well as indirectly by its immunosuppressive treatment ([@B60]). A potential confounding factor for these findings could be the administration of Rituximab for EBV infection, although this is most likely a minor factor in our study due the low numbers of patients receiving treatment and the equal distribution of EBV infection among the different *rs6897932* genotypes.

In conclusion, we have presented solid evidence that the donor *rs6897932* genotype of the IL-7Rα predicts aGVHD and cGVHD, CMV infection and TRM following allogeneic HSCT, without altering the risk of relapse. The biological background for the impact of this SNP may be alterations in the levels of soluble and membrane-bound IL-7R leading to stronger IL-7 signaling. Prospective studies should address the role of IL-7R genotyping as part of the donor selection process to reduce the incidence of treatment-related complications and its application as a pre-transplant biomarker identifying patients at risk and guiding prophylactic treatment.
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